{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Endometrial+Hyperplasia+With+Atypia&page=2", "query": { "condition": "Endometrial Hyperplasia With Atypia", "page": 2 }, "page_size": 10 }, "pagination": { "page": 2, "page_size": 10, "total_count": 26, "total_pages": 3, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Endometrial+Hyperplasia+With+Atypia&page=3&page_size=10", "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Endometrial+Hyperplasia+With+Atypia&page=1&page_size=10" }, "source": "remote", "last_synced_at": "2026-10-08T05:53:12.051Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT02035787", "title": "Metformin With the Levonorgestrel-Releasing Intrauterine Device for the Treatment of Complex Atypical Hyperplasia (CAH) and Endometrial Cancer (EC) in Non-surgical Patients", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Complex Atypical Hyperplasia", "Endometrial Cancer" ], "interventions": [ { "name": "Metformin", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "UNC Lineberger Comprehensive Cancer Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "FEMALE", "summary": "18 Years and older · Female only" }, "enrollment_count": 20, "start_date": "2014-02-27", "completion_date": "2024-04-12", "has_results": true, "last_update_posted_date": "2024-12-18", "last_synced_at": "2026-10-08T05:53:12.051Z", "location_count": 2, "location_summary": "Chapel Hill, North Carolina • Cincinnati, Ohio", "locations": [ { "city": "Chapel Hill", "state": "North Carolina" }, { "city": "Cincinnati", "state": "Ohio" } ], "official_url": "https://clinicaltrials.gov/study/NCT02035787" }, { "nct_id": "NCT00788671", "title": "Levonorgestrel-Releasing Intrauterine System in Treating Patients With Complex Atypical Hyperplasia or Grade I Endometrial Cancer", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Atypical Endometrial Hyperplasia", "Stage I Uterine Corpus Cancer AJCC v7", "Stage IA Uterine Corpus Cancer AJCC v7", "Stage IB Uterine Corpus Cancer AJCC v7", "Stage II Uterine Corpus Cancer AJCC v7" ], "interventions": [ { "name": "Laboratory Biomarker Analysis", "type": "OTHER" }, { "name": "Levonorgestrel-Releasing Intrauterine System", "type": "DEVICE" }, { "name": "Quality-of-Life Assessment", "type": "OTHER" } ], "intervention_types": [ "OTHER", "DEVICE" ], "sponsor": "M.D. Anderson Cancer Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "FEMALE", "summary": "18 Years and older · Female only" }, "enrollment_count": 69, "start_date": "2008-11-03", "completion_date": "2027-11-30", "has_results": true, "last_update_posted_date": "2025-08-15", "last_synced_at": "2026-10-08T05:53:12.051Z", "location_count": 7, "location_summary": "Houston, Texas • Nassau Bay, Texas • Sugar Land, Texas + 1 more", "locations": [ { "city": "Houston", "state": "Texas" }, { "city": "Houston", "state": "Texas" }, { "city": "Houston", "state": "Texas" }, { "city": "Houston", "state": "Texas" }, { "city": "Nassau Bay", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT00788671" }, { "nct_id": "NCT07107334", "title": "A Study to Estimate Early Clinical Efficacy Signals of GLP-1 Agonist Administration in Conjunction With Levonorgestrel Intrauterine Device in Obese Patients With Endometrioid Intraepithelial Neoplasia", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Endometrioid Endometrial Adenocarcinoma" ], "interventions": [ { "name": "Glucagon-like peptide 1 receptor agonist", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "University of Florida", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "FEMALE", "summary": "18 Years and older · Female only" }, "enrollment_count": 20, "start_date": "2026-04-07", "completion_date": "2029-11", "has_results": false, "last_update_posted_date": "2026-06-08", "last_synced_at": "2026-10-08T05:53:12.051Z", "location_count": 1, "location_summary": "Gainesville, Florida", "locations": [ { "city": "Gainesville", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT07107334" }, { "nct_id": "NCT04576104", "title": "Megestrol Acetate Compared With Megestrol Acetate and Metformin to Prevent Endometrial Cancer", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Endometrial Atypical Hyperplasia/Endometrioid Intraepithelial Neoplasia", "Endometrial Carcinoma" ], "interventions": [ { "name": "Biopsy Procedure", "type": "PROCEDURE" }, { "name": "Extended Release Metformin Hydrochloride", "type": "DRUG" }, { "name": "Megestrol Acetate", "type": "DRUG" }, { "name": "Questionnaire Administration", "type": "OTHER" } ], "intervention_types": [ "PROCEDURE", "DRUG", "OTHER" ], "sponsor": "Northwestern University", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 51, "start_date": "2021-11-29", "completion_date": "2026-06-30", "has_results": false, "last_update_posted_date": "2026-01-21", "last_synced_at": "2026-10-08T05:53:12.051Z", "location_count": 8, "location_summary": "Los Angeles, California • Denver, Colorado • Chicago, Illinois + 5 more", "locations": [ { "city": "Los Angeles", "state": "California" }, { "city": "Denver", "state": "Colorado" }, { "city": "Chicago", "state": "Illinois" }, { "city": "Winfield", "state": "Illinois" }, { "city": "Boston", "state": "Massachusetts" } ], "official_url": "https://clinicaltrials.gov/study/NCT04576104" }, { "nct_id": "NCT07078838", "title": "Tirzepatide in Women With Obesity and Endometrial Intra-epithelial Neoplasia or Grade 1 Endometrial Cancer", "overall_status": "NOT_YET_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Endometrial Cancer", "Endometrial Intraepithelial Neoplasia", "Grade 1 Endometrial Endometrioid Carcinoma" ], "interventions": [ { "name": "Tirzepatide", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "UNC Lineberger Comprehensive Cancer Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "FEMALE", "summary": "18 Years and older · Female only" }, "enrollment_count": 40, "start_date": "2027-01", "completion_date": "2029-03", "has_results": false, "last_update_posted_date": "2026-09-28", "last_synced_at": "2026-10-08T05:53:12.051Z", "location_count": 1, "location_summary": "Chapel Hill, North Carolina", "locations": [ { "city": "Chapel Hill", "state": "North Carolina" } ], "official_url": "https://clinicaltrials.gov/study/NCT07078838" }, { "nct_id": "NCT00503581", "title": "Megestrol in Treating Patients With Endometrial Neoplasia or Endometrial Hyperplasia", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "High Grade Squamous Intraepithelial Neoplasia", "Stage 0 Uterine Corpus Cancer" ], "interventions": [ { "name": "Biopsy", "type": "PROCEDURE" }, { "name": "Laboratory Biomarker Analysis", "type": "OTHER" }, { "name": "Megestrol Acetate", "type": "DRUG" }, { "name": "Pharmacological Study", "type": "OTHER" }, { "name": "Quality-of-Life Assessment", "type": "OTHER" }, { "name": "Therapeutic Conventional Surgery", "type": "PROCEDURE" } ], "intervention_types": [ "PROCEDURE", "OTHER", "DRUG" ], "sponsor": "Gynecologic Oncology Group", "sponsor_class": "NETWORK", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "FEMALE", "summary": "18 Years and older · Female only" }, "enrollment_count": 9, "start_date": "2007-07", "completion_date": null, "has_results": true, "last_update_posted_date": "2020-11-03", "last_synced_at": "2026-10-08T05:53:12.051Z", "location_count": 50, "location_summary": "Los Angeles, California • Sylmar, California • Hartford, Connecticut + 34 more", "locations": [ { "city": "Los Angeles", "state": "California" }, { "city": "Sylmar", "state": "California" }, { "city": "Hartford", "state": "Connecticut" }, { "city": "Hartford", "state": "Connecticut" }, { "city": "New Britain", "state": "Connecticut" } ], "official_url": "https://clinicaltrials.gov/study/NCT00503581" }, { "nct_id": "NCT07349641", "title": "A Study of Weight Loss Intervention With Tirzepatide and Progestin Intrauterine Device to Treat Endometrial Hyperplasia and Grade 1 Endometrial Cancer", "overall_status": "NOT_YET_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Endometrial Atypical Hyperplasia/Endometrioid Intraepithelial Neoplasia", "FIGO Grade 1 Endometrial Endometrioid Adenocarcinoma" ], "interventions": [ { "name": "Medical Device Usage and Evaluation", "type": "OTHER" }, { "name": "Tirzepatide", "type": "DRUG" } ], "intervention_types": [ "OTHER", "DRUG" ], "sponsor": "National Cancer Institute (NCI)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "FEMALE", "summary": "18 Years and older · Female only" }, "enrollment_count": 55, "start_date": "2026-11-01", "completion_date": "2030-10-31", "has_results": false, "last_update_posted_date": "2026-08-26", "last_synced_at": "2026-10-08T05:53:12.051Z", "location_count": 3, "location_summary": "Chicago, Illinois • Houston, Texas", "locations": [ { "city": "Chicago", "state": "Illinois" }, { "city": "Houston", "state": "Texas" }, { "city": "Houston", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT07349641" }, { "nct_id": "NCT07820358", "title": "Semaglutide, Weight Loss, and LNG-IUD for Conservative Treatment of Endometrial Atypical Hyperplasia and Grade 1 Endometrial Cancer", "overall_status": "NOT_YET_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Endometrial Atypical Hyperplasia", "Endometrial Atypical Hyperplasia/Endometrioid Intraepithelial Neoplasia", "Endometrial Cancer Stage I", "Endometrial Cancer", "Fertility-Sparing Treatment (FST)", "Obesity & Overweight" ], "interventions": [ { "name": "Semaglutide (Wegovy) weekly injection", "type": "DRUG" }, { "name": "LNG-IUD (Progestin)", "type": "DEVICE" }, { "name": "Structured Weight Loss Program", "type": "BEHAVIORAL" } ], "intervention_types": [ "DRUG", "DEVICE", "BEHAVIORAL" ], "sponsor": "The Methodist Hospital Research Institute", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "FEMALE", "summary": "18 Years and older · Female only" }, "enrollment_count": 48, "start_date": "2027-01-01", "completion_date": "2031-12-31", "has_results": false, "last_update_posted_date": "2026-10-01", "last_synced_at": "2026-10-08T05:53:12.051Z", "location_count": 4, "location_summary": "Houston, Texas", "locations": [ { "city": "Houston", "state": "Texas" }, { "city": "Houston", "state": "Texas" }, { "city": "Houston", "state": "Texas" }, { "city": "Houston", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT07820358" }, { "nct_id": "NCT02335203", "title": "The Effect of Neoadjuvant DMPA on Glandular Cellularity in Women Awaiting Hysterectomy", "overall_status": "UNKNOWN", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Grade 1 Endometrial Endometrioid Adenocarcinoma", "Grade 2 Endometrial Endometrioid Adenocarcinoma", "Complex Atypical Endometrial Hyperplasia" ], "interventions": [ { "name": "Depot medroxyprogesterone acetate", "type": "DRUG" }, { "name": "Placebo", "type": "OTHER" } ], "intervention_types": [ "DRUG", "OTHER" ], "sponsor": "Women and Infants Hospital of Rhode Island", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "FEMALE", "summary": "18 Years and older · Female only" }, "enrollment_count": 76, "start_date": "2015-02", "completion_date": "2018-06", "has_results": false, "last_update_posted_date": "2016-09-20", "last_synced_at": "2026-10-08T05:53:12.051Z", "location_count": 1, "location_summary": "Providence, Rhode Island", "locations": [ { "city": "Providence", "state": "Rhode Island" } ], "official_url": "https://clinicaltrials.gov/study/NCT02335203" }, { "nct_id": "NCT05463796", "title": "InAdvance: Surveillance, Prevention, and Interception in a Population at Risk for Cancer", "overall_status": "RECRUITING", "study_type": "OBSERVATIONAL", "phases": [], "conditions": [ "Cancer Risk", "Cancer Predisposition Syndrome", "Hereditary Cancer Prediction", "Childhood Cancer Survivors", "Adult Cancer Survivors", "IARC Carcinogens", "Smoking History", "Lung Cancer", "Ductal/Lobular Carcinoma", "Barrett Esophagus", "Pancreatic Precursor Lesions", "Colonic Dysplasia/Adenomata", "Non-Alcoholic Fatty Liver Disease", "Non Alcoholic Steatohepatitis", "Cirrhosis", "High Grade Prostatic Epithelial Neoplasia", "High-grade Bladder Urothelial Dysplasia/Carcinoma in Situ", "Adenomatous Hyperplasia", "High-risk Oral Precancerous Diseases", "Melanocytic Lesion, Adult", "Hematologic Malignancy", "Lung; Node", "Serous Tubal Intraepithelial Carcinoma", "Endometrial Intraepithelial Neoplasia", "Cervical and Endocervical Carcinoma in Situ", "Vulvar Intraepithelial Neoplasia", "Nephrogenic Rests", "Benign Bone Lesions With Risk of Malignant Degeneration", "Giant Cell Tumor", "Osteochondroma", "Spitz Nevus" ], "interventions": [ { "name": "Samples", "type": "OTHER" } ], "intervention_types": [ "OTHER" ], "sponsor": "Dana-Farber Cancer Institute", "sponsor_class": "OTHER", "healthy_volunteers": true, "eligibility": { "minimum_age": null, "maximum_age": null, "sex": "ALL", "summary": "Not listed" }, "enrollment_count": 5000, "start_date": "2023-04-25", "completion_date": "2031-03-25", "has_results": false, "last_update_posted_date": "2026-08-17", "last_synced_at": "2026-10-08T05:53:12.051Z", "location_count": 1, "location_summary": "Boston, Massachusetts", "locations": [ { "city": "Boston", "state": "Massachusetts" } ], "official_url": "https://clinicaltrials.gov/study/NCT05463796" } ] }